A Single Center, Open-Label, Three Periods, Fixed Sequence Design Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Neramexane (Primary) ; Rifampicin
- Indications Alzheimer's disease; Tuberculosis
- Focus Pharmacokinetics
- 11 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2009 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov
- 09 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.